Edit Symbol List
Don't know the stock symbol? Use the symbol lookup tool.
Alphabetize the sort order of my symbols
Company Description (as filed with the SEC)
We are a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. We are developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, we are developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and have partnered the development of a treatment for fibromyalgia. Product Pipeline: [[Image Removed]] Summary of Infectious Disease Programs: • Clostridium difficile (C. difficile) infections: In November 2012, we acquired a series of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention of C. ... More ...
|Annual EPS Est:||$-0.5|
|Quarterly EPS Est:||-0.07|